<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04052451</url>
  </required_header>
  <id_info>
    <org_study_id>MET-2-301</org_study_id>
    <nct_id>NCT04052451</nct_id>
  </id_info>
  <brief_title>The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder</brief_title>
  <official_title>The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuBiyota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NuBiyota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will measure the effects of MET-2 on symptoms of depression and anxiety using pre-
      and post-treatment scores for overall depression and anxiety and other symptoms of
      depression, such as sleep and anhedonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will measure the effects of MET-2 on symptoms of depression and anxiety using pre-
      and post-treatment scores for overall depression and anxiety and other symptoms of
      depression, such as sleep and anhedonia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an open label study with one arm for subjects diagnosed with major depression disorder and one arm for subjects diagnosed with generalized anxiety disorder</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Week 10</time_frame>
    <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Generalized Anxiety Disorder - 7 (GAD-7)</measure>
    <time_frame>Week 10</time_frame>
    <description>The GAD-7 is a seven domain, self-reported questionnaire for screening and assessing severity of generalized anxiety disorder.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Depression, Anxiety</condition>
  <arm_group>
    <arm_group_label>Major Depression Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MET-2 will be given to subjects with major depression disorder and its effect on mood will be measured</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Generalized Anxiety Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MET-2 will be given to subjects with generalized anxiety disorder and its effect on mood will be measured</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MET-2</intervention_name>
    <description>Subjects will take study medication once daily for the duration of the study</description>
    <arm_group_label>Generalized Anxiety Disorder</arm_group_label>
    <arm_group_label>Major Depression Disorder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to provide informed consent.

          2. Not pregnant

          3. Willing to participate in follow up as part of the study

          4. Diagnosis of MDD and/or GAD by MINI

          5. Current depressive episode with a MADRS score of ≥15 or Current GAD episode with GAD-7
             score of ≥8.

          6. Able to understand and comply with the requirements of the study

          7. Able to provide stool and blood samples.

        Exclusion Criteria:

          1. History of chronic diarrhea

          2. Need for regular use of agents that affect GI motility (narcotics such as codeine or
             morphine, agents such as loperamide or metoclopramide)

          3. Colostomy

          4. Elective surgery that will require preoperative antibiotics planned within 6 months of
             enrolment

          5. Pregnant, breastfeeding, or planning to get pregnant in the next 6 months

          6. Any condition for which, in the opinion of the investigator, the participant should be
             excluded from the study.

          7. Current use of any antidepressant/antianxiety drug (eligible to participate after a
             4-week washout period)

          8. Use of any antibiotic drug in the past 4 weeks (may be eligible to participate after a
             1-month washout period)

          9. History of alcohol or substance dependence in the past 6 months

         10. Daily use of probiotic product in the past 2 weeks (may be eligible to participate
             after a 2-week washout period)

         11. Use of any type of laxative in the last 2 weeks.

         12. Consumption of products fortified in probiotics

         13. High suicidal risk, as measured by MADRS item 10 score more than 3 (or 4)

         14. Current psychotic symptoms

         15. Bipolar Depression

         16. History of epilepsy or uncontrolled seizures

         17. Immunodeficiency (immuno-compromised and immuno-suppressed participants; e.g. acquired
             immune deficiency syndrome [AIDS], lymphoma, participants undergoing long-term
             corticosteroid treatment, chemotherapy and allograft participants)

         18. Unstable medical conditions or serious diseases/conditions (e.g. cancer,
             cardiovascular, renal, lung, diabetes, psychiatric illness, bleeding disorders, etc.)

         19. The use of natural health products (Natural health products [NHPs]; e.g. St. John's
             Wort, passion flower, etc.) that affect depression

         20. History of Electroconvulsive therapy (ECT)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arthi C Meyyappan</last_name>
    <phone>(613) 533-6360</phone>
    <email>14acm@queensu.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roumen Milev, MD,PhD</last_name>
    <phone>(613) 544-4900</phone>
    <phone_ext>73002</phone_ext>
    <email>milevr@providencecare.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Providence Care Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthi C Meyyappan</last_name>
      <phone>(613) 533-6360</phone>
      <email>14acm@queensu.ca</email>
    </contact>
    <contact_backup>
      <last_name>Roumen Milev, MD / PhD</last_name>
      <phone>(613) 544-4900</phone>
      <phone_ext>73002</phone_ext>
      <email>milevr@providencecare.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

